19178-21-3

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-5,6,7,8-tetrahydro-quinazolin-4-ol is used as an antiviral and anticancer agent due to its potential to target and inhibit the growth of viruses and cancer cells. Its bioactivity and ability to interact with specific biological targets make it a valuable compound for the development of new therapeutic agents.
Used in Neurological Disorders Treatment:
In the field of neurology, 2-Methyl-5,6,7,8-tetrahydro-quinazolin-4-ol is used as a potential treatment for neurological disorders and epilepsy. Its ability to modulate neuronal activity and influence neurotransmitter systems suggests that it may have therapeutic benefits for patients suffering from these conditions.
Used in Drug Development:
2-Methyl-5,6,7,8-tetrahydro-quinazolin-4-ol is used as a starting material or a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure and reactivity make it an attractive building block for the development of new drugs with improved efficacy and selectivity.

InChI:InChI=1/C9H12N2O/c1-6-10-8-5-3-2-4-7(8)9(12)11-6/h2-5H2,1H3,(H,10,11,12)

Upstream product

• 124-42-5 acetamidine hydrochloride 
• 1655-07-8 ethyl 2-oxocyclohexane carboxylate 
• 68965-62-8 2-bromocyclohex-1-enecarboxylic acid 
• 141419-94-5 ethyl 4-oxotetrahydro-2H-pyran-3-carboxylate 
• 105550-62-7 2-Methyl-2,3,5,6,7,8-hexahydro-1H-quinazolin-4-one 
• 143-37-3 acetamidine 
• 1404219-84-6 4-fluoro-2-methyl-5,6,7,8-tetrahydroquinazoline 1-oxide 
• 62360-62-7 7-exo-bromo-7-endo-fluorobicyclo<4.1.0>heptane 

Downstream Products

• 90561-38-9 4-chloro-2-methyl-5,6,7,8-tetrahydroquinazoline 

Relevant academic research and scientific papers

A novel and effective approach to 4-fluoropyrimidines

A series of 4-fluoropyrimidine 1-oxides, obtained via three-component heterocyclization, was studied under various reduction conditions. An effective preparative method for the synthesis of 4-fluoropyrimidines from readily available starting materials was elaborated. 4-Fluoro-substituted tetrahydroquinazolines and tetrahydroquinazoline N-oxides were demonstrated to be highly reactive in aromatic nucleophilic substitution.

Microwave-assisted copper-powder-catalyzed synthesis of pyrimidinones from β-bromo α,β-unsaturated carboxylic acids and amidines

β-Bromo α,β-unsaturated carboxylic acids were coupled and cyclized with amidine hydrochlorides by microwave irradiation in the presence of catalytic amounts of copper powder and a base to give the corresponding pyrimidinones in high yields. Georg Thieme Verlag Stuttgart New York.

Fe3O4 nanoparticle-supported copper(I): Magnetically recoverable and reusable catalyst for the synthesis of quinazolinones and bicyclic pyrimidinones

A highly efficient, easily recoverable and reusable Fe3O 4 magnetic nanoparticle-supported Cu(I) catalyst has been developed for the synthesis of quinazolinones and bicyclic pyrimidinones. In the presence of supported Cu(I) catalyst (10 mol%), amidines reacted with substituted 2-halobenzoic acids and 2-bromocycloalk-1-enecarboxylic acids to generate the corresponding N-heterocycle products in good to excellent yields at room temperature in DMF. In addition, the supported Cu(I) catalyst could be recovered at least 10 times without significant loss of its catalytic activity. Copyright

Easy and efficient copper-catalyzed synthesis of bicyclic pyrimidinones under mild conditions

A simple and efficient copper-catalyzed method has been developed for synthesis of bicyclic pyrimidinones containing six-, seven-, eight-membered rings under mild conditions. The protocol uses readily available 2-bromocycloalk-1-enecarboxylic acids, amidines, and guanidines as the starting materials, copper-catalyzed cascade couplings provide the corresponding bicyclic pyrimidinones without addition of any ligand or additive, and the method is of economical and practical advantages. Georg Thieme Verlag Stuttgart New York.

POLY(ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES

A medicament for therapeutic and/or preventive treatment of a brain disease, which comprises a compound represented by the following general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein R represents hydrogen atom, a C1-C8 alkyl group, a substituted C1-C8 alkyl group, an aryl group, a substituted aryl group, an aryl(C1-C8)alkyl group and the like; Y represents hydrogen atom or -C(R2)R3 (R2 and R3 represent hydrogen atom, a C1-C8 alkyl group, a C1-C8 alkoxy(C1-C8)alkyl group, a hydroxy(C1-C8)alkyl group and the like); symbol "a" represents single bond when Y represents hydrogen atom, or "a" represents double bound when Y represents -C(R2)R3; -A-B- represents -CH2-CH2-, -S-CH2-, -O-CH2-, -CH2-S-, -CH2-O-, -SO-CH2-, -CH2-SO-, -SO2-CH2-, or -CH2-SO2-; and Z represents -CH2- or single bond.

Pyrimidocycloalkanes as a II antagonists

There are disclosed compounds of the general formula I: STR1 wherein X is H, NR12 R13, OR14, CN, F, Cl, I, Br, perfluoroalkyl, alkyl, alkoxy, alkyl-OH, alkoxyalkyl, --(CH2)n CO2 R14/s

Alkyl-piperazinyl-5-6-alkylenepyrimidines

Compounds of formula (I) wherein one of R1 or R2 is piperazinyl or substituted piperazinyl and the other is alkyl or hydrogen possess oral hypoglycemic activity with the ability to lower blood sugar and are thus useful in the treatment of type II diabetes with associated insulin resistance.

A Novel Preparation of 5,6,7,8-Tetrahydroquinazolin-4(3H)-ones

Cyclocondensation of 2-oxocyclohexanecarboxamide with aldehydes and ammonia affords 4-oxo-1,2,5,6,7,8-hexahydroquinazolines which are conveniently dehydrogenated to the title compounds by treatment with palladium-on-carbon catalyst in boiling toluene.